Abstract
Experimental gene-therapeutic approaches for the prevention of restenosis after balloon angioplasty are the major source of our insight into pathways operative in the process of vascular renarrowing. We now understand that thrombosis and inflammation are the key mechanisms triggering vascular “healing” in response to injury and know a multitude of potential gene-therapeutic strategies to interfere with appositional thrombus formation, proliferation and migration of vascular smooth muscle cells, lesional recruitment of inflammatory cells or excess deposition of extracellular matrix. Thus far, the major limitation for clinical anti-restenotic gene therapy are concerns about the safety and efficacy of vector systems in use for the local overexpression of transgenes, which in turn is one of the most attractive advantages of gene therapy compared to systemic drug therapy. Here, we review the molecular mechanisms operative in postangioplasty restenosis by highlighting their respective gene therapeutic approaches and the current viral and non-viral vector systems.
Keywords: gene therapy, restenosis, balloon angioplasty, inflammation, smooth muscle cell proliferation, adenovirus
Current Vascular Pharmacology
Title: Gene Therapy Approaches for the Prevention of Restenosis
Volume: 2 Issue: 2
Author(s): Christoph W. Kopp and Rainer de Martin
Affiliation:
Keywords: gene therapy, restenosis, balloon angioplasty, inflammation, smooth muscle cell proliferation, adenovirus
Abstract: Experimental gene-therapeutic approaches for the prevention of restenosis after balloon angioplasty are the major source of our insight into pathways operative in the process of vascular renarrowing. We now understand that thrombosis and inflammation are the key mechanisms triggering vascular “healing” in response to injury and know a multitude of potential gene-therapeutic strategies to interfere with appositional thrombus formation, proliferation and migration of vascular smooth muscle cells, lesional recruitment of inflammatory cells or excess deposition of extracellular matrix. Thus far, the major limitation for clinical anti-restenotic gene therapy are concerns about the safety and efficacy of vector systems in use for the local overexpression of transgenes, which in turn is one of the most attractive advantages of gene therapy compared to systemic drug therapy. Here, we review the molecular mechanisms operative in postangioplasty restenosis by highlighting their respective gene therapeutic approaches and the current viral and non-viral vector systems.
Export Options
About this article
Cite this article as:
Kopp W. Christoph and Martin de Rainer, Gene Therapy Approaches for the Prevention of Restenosis, Current Vascular Pharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570161043476438
DOI https://dx.doi.org/10.2174/1570161043476438 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Opioid-induced Cardioprotection
Current Pharmaceutical Design Low Radiation Dose with Triple-Rule-Out CT Angiography in Diagnosis of Acute Chest Pain
Current Medical Imaging Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Hydrogen Gas Therapy: From Preclinical Studies to Clinical Trials
Current Pharmaceutical Design Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Non-ACE Pathway-induced Angiotensin II Production
Current Pharmaceutical Design New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Stroke in Women
Recent Patents on Cardiovascular Drug Discovery The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Recent Advances in Fluorescent Probes for Monitoring of Hydrogen Sulfide
Current Medicinal Chemistry Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology